Can Vraylar Cause Fatigue with Long-Term Use?
Yes, Vraylar (cariprazine) can cause fatigue with long-term use, and importantly, this side effect may emerge or persist weeks after starting the medication or increasing the dose due to the drug's prolonged presence in your body.
Understanding Vraylar's Unique Timing Profile
Vraylar has a critical characteristic that distinguishes it from other antipsychotics: it stays in your body for an extended period, meaning side effects like fatigue may not appear immediately but can develop weeks after initiation or dose increases 1. The FDA label explicitly warns that "late occurring side effects" can start several weeks after beginning treatment or after dose escalation, requiring healthcare providers to monitor patients for an extended period 1.
Documented Fatigue Rates
The evidence clearly demonstrates fatigue as a recognized adverse effect:
Bipolar Depression Treatment
- Fatigue occurred in 2-4% of patients taking Vraylar 1.5-3 mg daily compared to 3% on placebo in controlled trials 1
- Listed among common adverse reactions in the FDA labeling 1
Major Depressive Disorder (Adjunctive Treatment)
- In the 2025 pooled safety analysis of phase 2b/3 trials, fatigue was identified as a treatment-emergent adverse event, though specific rates varied by dose 2
- The 2020 bipolar depression study specifically noted fatigue among common adverse events occurring in ≥5% of patients at twice the placebo rate 3
Clinical Trial Data
- In schizophrenia trials, fatigue terms (including asthenia and fatigue) occurred in 3-4% of patients on therapeutic doses 1
Clinical Context and Management
The fatigue associated with Vraylar appears to be:
- Dose-related: Higher doses may increase the likelihood of fatigue
- Persistent in some patients: Due to the drug's long half-life and active metabolites
- Generally mild to moderate: Most treatment-emergent adverse events were mild/moderate in severity 2
- Rarely leading to discontinuation: Only 4.3% of patients discontinued due to adverse events in MDD trials, with fatigue not being a primary cause 2
Important Monitoring Considerations
Because Vraylar remains in the body for weeks:
- Monitor for fatigue development for several weeks after starting or increasing the dose 1
- If fatigue develops, it may take considerable time to resolve even after dose reduction or discontinuation
- The FDA specifically requires healthcare providers to monitor patients "for several weeks after you start and after any increase in your dose" 1
Practical Recommendations
If fatigue develops on Vraylar:
- Rule out other causes: Ensure fatigue isn't due to the underlying psychiatric condition, sleep disturbances, metabolic issues, or other medications
- Consider dose adjustment: Discuss with your prescriber whether a lower dose might maintain efficacy while reducing fatigue
- Time medication appropriately: Taking Vraylar at bedtime may help if daytime sedation is problematic
- Be patient with changes: Remember that any adjustment will take weeks to fully manifest due to the drug's pharmacokinetics
Critical Caveat
The 2026 expert consensus on cariprazine in schizophrenia management 4 and the 2025 real-world disability outcomes study 5 did not identify fatigue as a major limiting factor in clinical practice, suggesting that while fatigue occurs, it's generally manageable and doesn't significantly impair the drug's overall clinical utility or functional outcomes.
Bottom line: Fatigue is a documented side effect of Vraylar that can occur with long-term use, affects approximately 2-4% of patients above placebo rates, and may emerge weeks after starting or dose changes. However, it's typically mild-to-moderate and rarely causes treatment discontinuation.